相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan
Jian Guan et al.
MEDICAL ONCOLOGY (2016)
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Fiona Garner et al.
ANTI-CANCER DRUGS (2015)
Subglutinol A, an immunosuppressive α-pyrone diterpenoid from Fusarium subglutinans, acts as an estrogen receptor antagonist
Wonchung Lim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
New approaches for improving outcomes in breast cancer in Europe
Angelo Di Leo et al.
BREAST (2015)
Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
Gayathri Nagaraj et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Notch signaling: An emerging therapeutic target for cancer treatment
Xun Yuan et al.
CANCER LETTERS (2015)
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Janice Lu
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Investigation of (E)-344-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Donald P. McDonnell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
Anita Kort et al.
PHARMACEUTICAL RESEARCH (2015)
Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action
Yaghoub Safdari et al.
PHARMACOLOGICAL RESEARCH (2015)
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
David Berman et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Recent discoveries and developments of androgen receptor based therapy for prostate cancer
R. Elancheran et al.
MEDCHEMCOMM (2015)
Genistein induces apoptosis by the inactivation of the IGF-1R/p-Akt signaling pathway in MCF-7 human breast cancer cells
Jun Chen et al.
FOOD & FUNCTION (2015)
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
Annelies Gonnissen et al.
ONCOTARGET (2015)
Phase 2 Study of RO4929097, a Gamma-Secretase Inhibitor, in Metastatic Melanoma: SWOG 0933
Sylvia M. Lee et al.
CANCER (2015)
Recent advances in the field of anti-cancer immunotherapy
Henrique Neves et al.
BBA CLINICAL (2015)
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
J. M. Nabholtz et al.
ANNALS OF ONCOLOGY (2014)
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
Robert Coleman et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
Leanne Stalker et al.
CANCER CELL INTERNATIONAL (2014)
Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials
Andre F. Caryalho et al.
CANCER TREATMENT REVIEWS (2014)
Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer
Thehang Luu et al.
CLINICAL BREAST CANCER (2014)
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer
Lorelei A. Mucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
Parvin F. Peddi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Dual HER2 blockade: preclinical and clinical data
Tejal A. Patel et al.
BREAST CANCER RESEARCH (2014)
Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3 '-Diindolylmethane: A Therapeutic Marvel
V. L. Maruthanila et al.
ADVANCES IN PHARMACOLOGICAL SCIENCES (2014)
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Tina Sharma et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John F. R. Robertson et al.
LANCET ONCOLOGY (2013)
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
Alberto J. Montero et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
Aman Buzdar et al.
CANCER (2012)
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy
Brian J. Park et al.
CANCER LETTERS (2012)
Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
Dedra H. Fagan et al.
CANCER RESEARCH (2012)
Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
Bhuvaneswari Ramaswamy et al.
CANCER RESEARCH (2012)
Overexpression of Gli1 in cancer interstitial tissues predicts early relapse after radical operation of breast cancer
Ying-Hua Li et al.
CHINESE JOURNAL OF CANCER RESEARCH (2012)
Role of Estrogen Receptor Signaling in Breast Cancer Metastasis
Sudipa Saha Roy et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial
P. D. Ryan et al.
CANCER RESEARCH (2011)
Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
Jin Gao et al.
CANCER RESEARCH (2011)
Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer
Masae Souzaki et al.
CANCER SCIENCE (2011)
Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines
Yeon-Jin Kwon et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study
Tobias Baeuerle et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen
Naomi Suzuki et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Notch Signaling Pathway as a Therapeutic Target in Breast Cancer
Hamed Al-Hussaini et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Therapeutic targets for bone metastases in breast cancer
Philippe Clezardin
BREAST CANCER RESEARCH (2011)
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2010)
Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions
Y. R. Santosh Laxmi et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
D. Sachdev et al.
ONCOGENE (2010)
Antiovulatory effect of a single injection of pure antiestrogen ZK 191703 at early stage of rat estrus cycle
Tsuyuki Nishino et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2009)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer
M Kubo et al.
CANCER RESEARCH (2004)
Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion
N Platet et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
分享论文
